1800-272-662
Shopping Cart 0
countryflagAU
Login

Vectus Biosystems Ltd

Healthcare AU VBS

0.13AUD
0.005(4.00%)

Last update at 2026-03-13T04:34:00Z

Day Range

0.120.13
LowHigh

52 Week Range

0.040.46
LowHigh

Fundamentals

  • Previous Close 0.12
  • Market Cap6.68M
  • Volume6113
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.38339M
  • Revenue TTM0.09M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 0.09M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -1.77726M -3.39906M -3.44886M -3.99377M -4.79765M
Minority interest - - - - -
Net income -1.77726M -2.33812M -3.44886M -4.68726M -4.28257M
Selling general administrative 0.95M 0.78M 2.57M 2.04M 2.07M
Selling and marketing expenses 0.55M 1.48M - - -
Gross profit 0.48M 1.14M - - 0.00018M
Reconciled depreciation - 0.06M 0.05M 0.02M 0.02M
Ebit -1.70143M -2.32942M -3.24334M -3.30029M -3.72338M
Ebitda -1.68774M -2.27059M -3.19613M -3.28010M -3.70596M
Depreciation and amortization 0.01M 0.06M 0.05M 0.02M 0.02M
Non operating income net other - - - - -
Operating income -1.68774M -2.27059M -3.24334M -3.30029M -2.78697M
Other operating expenses 2.17M 3.41M 4.60M 4.60M 3.81M
Interest expense 0.00391M 0.00870M 0.21M 0.69M 1.07M
Tax provision - 0.00000M 0.00000M 0.00000M -0.51508M
Interest income 0.00167M 0.08M 0.06M 0.00008M 0.00022M
Net interest income - 0.07M -0.15001M -0.69340M -1.07405M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.46118M -1.06094M 1.50M 0.69M -0.51508M
Total revenue 0.48M 1.14M 0.06M 1.30M 0.00018M
Total operating expenses 2.17M 3.41M 4.60M 4.60M 3.80M
Cost of revenue - 0.06M - - -
Total other income expense net -0.08952M -1.12848M 1.30M -0.69349M 0.08M
Discontinued operations - - - - -
Net income from continuing ops - -2.33812M -3.44886M -3.99377M -4.28257M
Net income applicable to common shares -1.77726M -2.33812M -3.44886M -3.99377M -4.28257M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 0.78M 2.03M 4.63M 3.94M 6.04M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.09M 0.06M 1.43M 2.32M 0.04M
Total liab 1.04M 0.57M 1.11M 7.47M 8.87M
Total stockholder equity -0.25662M 1.45M 3.52M -3.53399M -2.82260M
Deferred long term liab - - - - -
Other current liab 0.30M 0.37M 0.36M 0.89M 0.44M
Common stock 38.37M 38.37M 38.35M 27.30M 24.83M
Capital stock - - 38.35M 28.19M 25.85M
Retained earnings -39.50328M -37.76152M -35.63172M -32.18286M -29.12549M
Other liab - - 0.00298M 0.07M 0.00164M
Good will - - - - -
Other assets - - - - -
Cash 0.25M 0.81M 2.95M 1.28M 5.78M
Cash and equivalents - - - - -
Total current liabilities 0.84M 0.57M 1.08M 7.40M 1.66M
Current deferred revenue - - 0.45M 0.44M 0.43M
Net debt -0.05099M -0.78004M -2.88075M 4.73M 1.89M
Short term debt - 0.03M 0.04M 5.95M 0.46M
Short long term debt - - - 5.89M 0.44M
Short long term debt total 0.20M 0.03M 0.07M 6.02M 7.67M
Other stockholder equity - - -2.72036M 0.89M 1.01M
Property plant equipment - - 0.17M 0.21M 0.07M
Total current assets 0.78M 1.84M 4.46M 3.73M 5.97M
Long term investments - - - - -
Net tangible assets - - 3.52M -3.53399M -2.82260M
Short term investments - - - - -
Net receivables 0.44M 0.98M 0.07M 0.13M 0.15M
Long term debt - - - 0.00000M 7.19M
Inventory 0.00098M 0.00098M 0.00098M 0.00040M 0.00040M
Accounts payable 0.53M 0.17M 0.22M 0.12M 0.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.88M 0.84M 0.80M 0.46M 0.45M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -0.17311M -0.20751M -0.07335M
Deferred long term asset charges - - - - -
Non current assets total 0.00421M 0.18M 0.17M 0.21M 0.07M
Capital lease obligations - - 0.07M 0.13M 0.04M
Long term debt total - - 0.03M 0.07M 7.21M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -0.06790M -0.01713M - -
Change to liabilities - - 0.10M -0.20119M -0.27120M
Total cashflows from investing activities 0.10M -0.06790M -0.01713M -0.02100M -0.02100M
Net borrowings - - -0.49814M -0.03455M -0.53830M
Total cash from financing activities 0.17M -0.04128M 4.04M -0.03455M 6.35M
Change to operating activities - - 0.71M -0.76994M 0.03M
Net income -1.77726M -2.33812M -3.44886M -3.99377M -3.86124M
Change in cash -0.55798M -2.14199M 1.67M -4.49678M 3.09M
Begin period cash flow 0.81M 2.95M 1.28M 5.78M 2.69M
End period cash flow 0.25M 0.81M 2.95M 1.28M 5.78M
Total cash from operating activities -0.83009M -2.03281M -2.35274M -4.44123M -3.25553M
Issuance of capital stock - - 4.60M - 7.00M
Depreciation 0.01M 0.06M 0.05M 0.02M 0.02M
Other cashflows from investing activities 0.10M - - 0.00000M -
Dividends paid - - - 4.10M -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 0.00000M -0.06295M -0.06295M -0.11333M
Other cashflows from financing activities - -0.04128M -0.05585M -0.03455M -0.02322M
Change to netincome - - 0.23M 0.48M 1.25M
Capital expenditures 0.00000M 0.07M 0.02M 0.02M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.64M 0.24M 2.20M 0.00016M 0.54M
Stock based compensation 0.03M 0.06M 0.00206M 0.00864M 0.19M
Other non cash items 0.26M -0.04957M 1.05M -0.47628M 0.40M
Free cash flow -0.83009M -2.10071M -2.36987M -4.46223M -3.25553M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VBS
Vectus Biosystems Ltd		 0.005 4.00% 0.13 - - 74.24 7.94 156321.21 -8.5783
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. The company was incorporated in 2005 and is based in Rosebery, Australia.

Vectus Biosystems Ltd

26-34 Dunning Avenue, Rosebery, NSW, Australia, 2018

Key Executives

Name Title Year Born
Dr. Karen Annette Duggan CEO & Exec. Director NA
Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin Company Sec. NA
Prof. Graham Jon MacDonald AM, M.D., BSc (Med), BS, FRACP, FRCP, FANZCC Consultant NA
Dr. Karen Annette Duggan CEO & Executive Director NA
Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin Company Secretary NA
Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D. Consultant NA
Dr. Karen Annette Duggan CEO & Executive Director NA
Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin Company Secretary NA
Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D. Consultant NA
Dr. Karen Annette Duggan CEO & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.